A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, and -A33

Cancer Immunology, Immunotherapy

Volumn 56, Issue 9, 2007, Pages 1359-1366

  Matsueda, Satoko ^a   Yamada, Akira ^a,b   Takao, Yukari ^a   Tamura, Mayumi ^a   Komatsu, Nobukazu ^a,b   Yutani, Shigeru ^a   Ide, Tatsuya ^a   Sata, Michio ^a   Itoh, Kyogo ^a,b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

CTL; Epitope; HCV; Hepatitis; HLA A3; Peptide vaccine

Indexed keywords

ASPARAGINYLLEUCYLTYROSYLGLUTAMYLLYSYLVALYLLYSINE; ASPARTYLARGINYLLYSYLSERYLASPARTYLALANYLLYSINE; CORE PROTEIN; EPITOPE; HLA A ANTIGEN; HLA A11 ANTIGEN; HLA A31 ANTIGEN; HLA A33 ANTIGEN; IMMUNOGLOBULIN G; ISOLEUCYLVALYLGLYCYLGLYCYLVALYLTYROSYLLEUCYLLEUCYLPROLYLARGININE; LEUCYLISOLEUCYLARGINYLALANYLCYSTEINYLMETHIONYLLEUCYLVALYLARGININE; TYROSYLLEUCYLLEUCYLPROLYLARGINYLARGINYLGLYCYLPROLYLARGININE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLOGENEIC RESTRICTION; ANTIBODY SCREENING; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LIVER CARCINOGENESIS; MALE; PRIORITY JOURNAL; PROTEIN BINDING;

ADULT; AGED; AMINO ACID SEQUENCE; CELL LINE; EPITOPES; FEMALE; HEPACIVIRUS; HEPATITIS C; HLA-A ANTIGENS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34347396382     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0284-5     Document Type: Article

References (27)

1. Aizawa M (1986) The proceedings of the 3rd Asia-Oceania histocompatibility workshop conference. Oxford University Press, Oxford, pp 1090-1103
2. Alexander J, Oseroff C, Sidney J, Wentworth P, Keogh E, Hermanson G, Chisari FV, Kubo RT, Grey HM, Sette A (1997) Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes. J Immunol 159:4753-4761
3. Battegay M, Fikes J, Di Bisceglie AM, Wentworth PA, Sette A, Celis E, Ching WM, Grakoui A, Rice CM, Kurokohchi K, et al (1995) Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 69:2462-2470
4. Cerny A, McHutchinson J, Pasquellini C, Brown M, Brothers M, Grabschied B, Fowler P, Houghton M, Chisari F (1995) CTL response to HCV-derived peptides containing the HLA-A2.1 binding motif. J Clin Invest 95:521-530
5. Chang KM, Gruener NH, Southwood S, Sidney J, Pape GR, Chisari FV, Sette A (1999) Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol 162:1156-1164
6. Gruener NH, Jung MC, Ulsenheimer A, Gerlach JT, Zachoval R, Diepolder HM, Baretton G, Schauer R, Pape GR, Schirren CA (2004) Analysis of a successful HCV-specific CD8+ T cell response in patients with recurrent HCV-infection after orthotopic liver transplantation. Liver Transpl 10:1487-1496
7. Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, Houghton M, Walker BD (1995) HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 96:2311-2321
8. Kurokohchi K, Arima K, Nishioka M (2001) A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection. J Hepatol 34:930-935
9. Lopez-Labrador FX, He XS, Berenguer M, Cheung RC, Gonzalez-Candelas F, Wright TL, Greenberg HB (2004) Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C. J Med Virol 72:575-585
10. Mine T, Gouhara R, Hida N, Imai N, Azuma K, Rikimaru T, Katagiri K, Nishikori M, Sukehiro A, Nakagawa M, Yamada A, Aizawa H, Shirouzu K, Itoh K, Yamana H (2003) Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 94:548-556
11. Missale G, Redeker A, Person J, Fowler P, Guilhot S, Schlicht HJ, Ferrari C, Chisari FV (1993) HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med 177:751-762
12. Mizukoshi E, Nascimbeni M, Blaustein JB, Mihalik K, Rice CM, Liang TJ, Feinstone SM, Rehermann B (2002) Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies. J Virol 76:6093-6103
13. Parker KC, Bednarek MA, Cokigan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163-175
14. Rammensee HG, Friede T, Stevanoviic S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41:178-228
15. Sarobe P, Huarte E, Lasarte JJ, Lopez-Diaz de Cerio A, Garcia N, Borras-Cuesta F, Prieto J (2001) Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes. J Hepatol 34:321-329
16. Sato Y, Shomura H, Maeda Y, Mine T, Une Y, Akasaka Y, Kondo M, Takahashi S, Shinohara T, Katagiri K, Sato M, Okada S, Matsui K, Yamada A, Yamana H, Itoh K, Todo S (2002) Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 94:802-808
17. Seeff LB (2002) Natural history of chronic hepatitis C. Hepatology 36:S35-S46
18. Sette A, Sidney J (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50:201-212
19. Sidney J, Grey HM, Southwood S, Celis E, Wentworth PA, del Guercio MF, Kubo RT, Chesnut RW, Sette A (1996) Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol 45:79-93
20. Takao Y, Yamada A, Yutani S, Sata M, Itoh K (2004) Antibody reactive to a hepatitis C virus (HCV)-derived peptide capable of inducing HLA-A2 restricted cytotoxic T lymphocytes is detectable in a majority of HCV-infected individuals without HLA-A2 restriction. Microbiol Immunol 48:507-517
21. + cancer patients. Clin Cancer Res 10:1112-1120
22. Tamura M, Yamada A, Takao Y, Matsueda S, Komatsu N, Yutani S, Ide T, Sata M, Itoh K (2005) Identification of hepatitis C virus 1b-derived peptides recognized by both cellular and humoral immune systems in HCV1b(+) HLA-A24(+) patients. Hepatol Res 32:227-234
23. Tsuda N, Mochizuki K, Harada M, Sukehiro A, Kawano K, Yamada A, Ushijima K, Sugiyama T, Nishida T, Yamana H, Itoh K, Kamura T (2004) Vaccination with pre-designated or evidence based peptides for patients with recurrent gynecologic cancers. J Immunother 27:60-72
24. Urbani S, Uggeri J, Matsuura Y, Miyamura T, Penna A, Boni C, Ferrari C (2001) Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens. Hepatology 33:1533-1543
25. Wentworth PA, Sette A, Celis E, Sidney J, Southwood S, Crimi C, Stitely S, Keogh E, Wong NC, Livingston B, Alazard D, Vitiello A, Grey HM, Chisari FV, Chesnut RW, Fikes J (1996) Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. Int Immunol 8:651-659
26. World Health Organization (WHO) (2006) Hepatitis C. Available at: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2. html#disease%20burden
27. Zein NN (2000) Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 13:223-235